Study Results from Tehran University of Medical Sciences Provide New Insights into Migraine (Cost-utility Analysis of Erenumab Compared To Topiramate for Preventive Therapy of Migraine In Iran).

A study conducted by Tehran University of Medical Sciences in Iran compared the cost-effectiveness of Erenumab and Topiramate for migraine treatment in Iran. The research found that Erenumab was not cost-effective compared to Topiramate based on current prices, with an incremental cost-effectiveness ratio significantly higher than the Iranian willingness-to-pay threshold. The study suggests that for Erenumab to be considered cost-effective in Iran, a significant price reduction is necessary for its entry into the pharmaceutical market. [Extracted from the article]